RecruitingPhase 2NCT06811233

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Sponsor

M.D. Anderson Cancer Center

Enrollment

140 participants

Start Date

May 8, 2025

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia (AML)

Summary

The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2 study is investigating whether monitoring and adjusting metal levels (such as copper and zinc) in the blood during acute myeloid leukemia (AML) treatment can improve outcomes. Certain metals become imbalanced during leukemia and its treatment, and researchers think rebalancing them may help. **You may be eligible if...** - You are 18 or older with a new or previously untreated diagnosis of AML or a related blood cancer (such as MPN in blast phase) - Your AML is classified as intermediate or high-risk - You are willing to have blood metal levels monitored and potentially treated **You may NOT be eligible if...** - You have certain lower-risk AML subtypes (core binding factor AML) - You have already received AML treatment - You have conditions that would affect metal metabolism testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.